|  |
| --- |
| **COVID Medicine Delivery Unit (CMDU) REFERRAL FORM**  Date of GP decision to refer:<Today's date> No. of pages sent: |

PLEASE COMPLETE PROFORMA **WITHIN 24HRS** OF REQUEST AND EMAIL TO CDMU [**blmkicb.cmdu@nhs.net**](mailto:blmkicb.cmdu@nhs.net)

**The CMDU will assess the patient within 48 hours following receipt of referral.**

PROFORMA CAN BE FOUND ON THE COMMUNITY REFERRALS TAB IN ARDENS ON SYSTMONE

This proforma is NOT for use for:

Patients aged < 12 years, children <40kg, patients who are asymptomatic, patients showing signs of clinical improvement or patients requiring hospitalisation/new need for O2.

|  |
| --- |
| **GP DETAILS** |
| GP name: <Sender Name> |
| Practice Code: <Organisation Details>  Address: <Organisation Details>,  <Organisation Address>  TEL: <Sender Details>  Practice email: <Organisation Details> |

|  |
| --- |
| **PATIENT DETAILS**  Referrer must provide a current telephone number. |
| Last name: <Patient Name> First name: <Patient Name> |
| Gender: <Gender> DOB: <Date of Birth> |
| BMI (*assists diagnostics*): <Numerics>  NHS No: <NHS number> |
| Address: <Patient Address> |
| Email:<Patient Contact Details>  Telephone (Day): <Patient Contact Details> |
| Telephone (Evening): <Patient Contact Details> |
| Mobile No.: <Patient Contact Details> |
| Patient agrees to telephone message being left. Y  N |
| Transport required? Y |
| Interpreter required? Y  Language/Hearing:  <Main spoken language> |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
| **ELIGIBILITY:** | | | |
| Date of positive LFT : | | | |
| Date of symptom onset: | | | |
| Patient remains symptomatic i.e. no evidence of clinical improvement: | | | |
| **Highest risk patient cohort group for ADULTS (18 years and older) (Full details available in Box 1 of** [Risk factors for progression to severe COVID‑19](https://www.nice.org.uk/guidance/ta878/chapter/supporting-information-on-risk-factors-for-progression-to-severe-covid19#supporting-information-on-risk-factors-for-progression-to-severe-covid19) **)** | | | |
|  | Down’s syndrome and other genetic disorders  Solid cancer  Haematological diseases  Recipients of haematological stem cell transplant  Renal disease  Liver diseases |  | Solid organ transplant recipients  Immune-mediated inflammatory disorders  Respiratory  Immune deficiencies  HIV / AIDS  Neurological disorders |
| **Highest risk patient cohort group for CHILDREN AND YOUNG PEOPLE (greater than 40kg, aged 12-17 years) (Full details available in Box 2 of** [Risk factors for progression to severe COVID‑19](https://www.nice.org.uk/guidance/ta878/chapter/supporting-information-on-risk-factors-for-progression-to-severe-covid19#supporting-information-on-risk-factors-for-progression-to-severe-covid19) **)** | | | |
|  | **Those at substantial risk:**  Complex life-limiting neurodisability with recurrent respiratory infections or compromise. |  | **Those at significant risk if 2 or more of these risk factors are present:**  Primary immunodeficiency  Secondary immunodeficiency  Immunosuppressive treatment  Other conditions |

|  |
| --- |
| **Reason for Referral:**    <Event Details> |
| **Medical Problems:** |

|  |  |
| --- | --- |
| **PATIENT MEDICAL HISTORY** | |
| **Medical Problems:**  <Problems>  <Summary> | |
| **Medication:** | |
| Acutes | <Medication> |
| Repeats | <Repeat templates> |
| **Allergies:**  <Allergies & Sensitivities> | |

**Minimum Dataset:** (recordings in last 6months)

|  |  |  |  |
| --- | --- | --- | --- |
| **Blood Pressure** | <Latest BP>, <Numerics> | | |
| **Heart rate** | <Numerics>, <Diagnoses> | | |
| **Height** | <Numerics> | **Smoking Status** | <Diagnoses>, <Numerics> |
| **Weight** | <Numerics> | **Alcohol Intake** | <Diagnoses>, <Numerics> |
| **BMI** | <Numerics> | **Exercise tolerance:** | <Diagnoses><Diagnoses> |

**Blood Results** (Last 12m):

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **FBC** | <Numerics> | Hb <Numerics>, WCC <Numerics>, Plts <Numerics>, MCV <Numerics>, Neut <Numerics> | | |
| **UE** | <Numerics> | Na <Numerics>, K <Numerics>, Urea <Numerics>, Creat <Numerics>, eGFR <Numerics> | | |
| **LFT** | <Numerics> | ALT <Numerics>, Alk Phos <Numerics>, Bili <Numerics>, Alb <Numerics>, GGT <Numerics>, Serum globulin <Numerics>, Total Protein <Numerics> | | |
| **CRP** | <Numerics> | <Numerics> | **ESR** | <Numerics> |
| **TFTs** | <Numerics> | TSH <Numerics>, Free T4 <Numerics> | **INR** | <Numerics> |
| **Bone** | <Numerics> | Ca <Numerics>, Ca cor <Numerics>, Ca adj <Numerics>, Phos <Numerics> | | |
| **Iron** | <Numerics> | Ferritin <Numerics>, Iron Saturation <Numerics>, TIBC <Numerics> | | |
| **Vitamins** | <Numerics> | B12 <Numerics>, Folate <Numerics> | | |
| **Lipids** | <Numerics> | Chol <Numerics>, LDL <Numerics>, HDL <Numerics>,Chol:HDL ratio <Numerics>, Tri <Numerics> | | |
| **Random Glucose** | | <Numerics> | **Fasting Chol.** | <Numerics> |
| **Fasting Glucose** | | <Numerics> | **HbA1c** | <Numerics> |

**Full referral eligibility is within the NICE TA – link below**

[5 Supporting information on risk factors for progression to severe COVID‑19 | Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | Guidance | NICE](https://www.nice.org.uk/guidance/ta878/chapter/supporting-information-on-risk-factors-for-progression-to-severe-covid19#supporting-information-on-risk-factors-for-progression-to-severe-covid19)